Concomitant chemoradiotherapy and antiretroviral therapy for HIV-infected patients with locoregionally advanced non-small cell lung cancer: Benefit and tolerability of treatment in 2 cases

Onkologie(Czech Republic)

Volumn 36, Issue 10, 2013, Pages 586-590

  Okuma, Yusuke ^a,b   Yanagisawa, Naoki ^b   Hosomi, Yukio ^a   Imamura, Akifumi ^b   Okamura, Tatsuru ^a   Kato, Kan ^a   Negishi, Kyota ^c  

^a Department of Thoracic Oncology and Respiratory Medicine ^*  (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c Tokyo Kensei Hospital   (Japan)

Author keywords

Chemoradiotherapy; HAART; Highly active antiretroviral therapy; HIV; Human immunodeficiency virus; Locoregionally advanced NSCLC; Non AIDS defining cancers; Non small cell lung cancer; NSCLC

Indexed keywords

CISPLATIN; DOCETAXEL; EFAVIRENZ; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; LAMIVUDINE; LOPINAVIR; RALTEGRAVIR; RITONAVIR; TENOFOVIR;

ADVANCED CANCER; AGED; ANTIVIRAL THERAPY; ARTICLE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; RADIATION DOSE;

AGED; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HIV INFECTIONS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 84885589975     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000355162     Document Type: Article

References (24)

1. Sepkowitz KA: AIDS - the first 20 years. N Engl J Med 2001;344:1764-1772.
2. Lavole A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J: Lung cancer, a new challenge in the HIV-infected population. Lung Cancer 2006;51:1-11.
3. D'Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ, Stebbing J, Aboulafia DM: Human immunodeficiency virus-Associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010;11:396-404.
4. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD: Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006;24:1383-1388.
5. Alshafie MT, Donaldson B, Oluwole SF: Human immunodeficiency virus and lung cancer. Br J Surg 1997;84:1068-1071.
6. Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B: HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003;17:371-375.
7. Lavole A, Cadranel J: (Lung cancer in patients with HIV infection: an emerging problem). Rev Pneumol Clin 2004;60:4S39-34S43.
8. Karp J, Profeta G, Marantz PR, Karpel JP: Lung cancer in patients with immunodeficiency syndrome. Chest 1993;103:410-413.
9. Flores MR, Sridhar KS, Thurer RJ, Saldana M, Raub WA Jr, Klimas NG: Lung cancer in patients with human immunodeficiency virus infection. Am J Clin Oncol 1995;18:59-66.
10. Bazoes A, Bower M, Powles T: Smoke and mirrors: HIV-related lung cancer. Curr Opin Oncol 2008; 20:529-533.
11. Giordano TP, Kramer JR: Does HIV infection independently increase the incidence of lung cancer? Clin Infect Dis 2005;40:490-491.
12. Pakkala S, Chen Z, Rimland D, Owonikoko TK, Gunthel C, Brandes JR, Saba NR, Shin DM, Curran WJ Jr, Khuri FR, Ramalingam SS: Human immunodeficiency virus-Associated lung cancer in the era of highly active antiretroviral therapy. Cancer 2011;118:164-172.
13. Cadranel J, Garfield D, Lavole A, Wislez M, Milleron B, Mayaud C: Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 2006;61:1000-1008.
14. Hakimian R, Fang H, Thomas L, Edelman MJ: Lung cancer in HIV-infected patients in the era of highly active antiretroviral therapy. J Thorac Oncol 2007;2:268-272.
15. Rengan R, Mitra N, Liao K, Armstrong K, Vachani A: Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012;13:1203-1209.
16. Kaminuma T, Karasawa K, Hanyu N, Chang TC, Kuga G, Okano N, Kubo N, Okuma Y, Nagata Y, Maeda Y, Ajisawa A: Acute adverse effects of radiation therapy on HIV-positive patients in Japan: study of 31 cases at Tokyo Metropolitan Komagome Hospital. J Radiat Res (Tokyo) 2010;51:749-753.
17. Chak LY, Gill PS, Levine AM, Meyer PR, Anselmo JA, Petrovich Z: Radiation therapy for acquired immunodeficiency syndrome-related Kaposi's sarcoma. J Clin Oncol 1988;6:863-867.
18. Cooper JS, Fried PR, Laubenstein LJ: Initial observations of the effect of radiotherapy on epidemic Kaposi's sarcoma. JAMA 1984;252:934-935.
19. Buhl R, Jaffe HA, Holroyd KJ, Wells FB, Mastrangeli A, Saltini C, Cantin AM, Crystal RG: Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989;2:1294-1298.
20. Vallis KA: Glutathione deficiency and radiosensitivity in aids patients. Lancet 1991;337:918-919.
21. Chapman CH, Shen J, Filion EJ, Tran PT, Hara W, Asuncion A, Marko D, Wakelee H, Berry GJ, Dimmick KW, Loo BW Jr, Green J: Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency viruspositive patient taking nelfinavir. J Thorac Oncol 2009;4:1587-1589.
22. Brunner TB, Geiger M, Grabenbauer GG, Lang- Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG: Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26:2699-2706.
23. Sanchez X, Cousins-Hodges B, Aguilar T, Gosselink P, Lu Z, Navarro J: Activation of HIV-1 coreceptor (CXCR4) mediates myelosuppression. J Biol Chem 1997;272:27529-27531.
24. Chow WA, Jiang C, Guan M: Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 2009;10:61-71.